How many drugs treat Extrapyramidal disease?

Drug Landscape tracks 5 marketed treatments for Extrapyramidal disease (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/extrapyramidal-disease.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Extrapyramidal disease — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Extrapyramidal disease (disease) competitive landscape: 5 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

5 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Extrapyramidal disease, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Gocovri	AMANTADINE	Endo	Influenza A M2 Protein Inhibitor	Sigma non-opioid intracellular receptor 1	1968-01-01
Akineton	BIPERIDEN	AbbVie	Anticholinergic	Muscarinic acetylcholine receptor M1	1959-01-01
Cogentin	Cogentin	University of Southern California		5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B
GOCOVRI	GOCOVRI	Oregon Health and Science University	Influenza A M2 Protein Inhibitor	Sigma non-opioid intracellular receptor 1
Amantadin	Amantadin	Centre Hospitalier Universitaire de Nice		Multidrug and toxin extrusion protein 1, Sigma non-opioid intracellular receptor 1, Glutamate [NMDA] receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 4 drugs in Extrapyramidal disease
AbbVie · 1 drug in Extrapyramidal disease
Centre Hospitalier Universitaire de Nice · 1 drug in Extrapyramidal disease
Endo · 1 drug in Extrapyramidal disease
Oregon Health and Science University · 1 drug in Extrapyramidal disease
University of Southern California · 1 drug in Extrapyramidal disease

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Extrapyramidal disease:

Cite this brief

Drug Landscape (2026). Extrapyramidal disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/extrapyramidal-disease. Accessed 2026-06-10.

Extrapyramidal disease full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing